Litigation Details for Genzyme Corp. v. Cipla Limited (D. Del. 2018)

Genzyme Corp. v. Cipla Limited (D. Del. 2018)

Docket	1:18-cv-01838	Date Filed	2018-11-20
Court	District Court, D. Delaware	Date Terminated	2019-10-08
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,916,802; 7,196,205; 7,253,185; 7,615,573
Link to Docket	External link to docket

Details for Genzyme Corp. v. Cipla Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-20				External link to document
2018-11-19	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,196,205 B2; 6,916,802 B2; 7,253,185…2018 8 October 2019 1:18-cv-01838 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Genzyme Corp. v. Cipla Ltd. (1:18-cv-01838)

Last updated: July 9, 2026

Executive summary: Genzyme Corp. sued Cipla Limited in the U.S. District Court for the District of Massachusetts under Hatch-Waxman to block approval of a competing product, asserting infringement of Genzyme’s Orange Book-linked patents tied to the protected drug product at issue in the case Genzyme Corp. v. Cipla Ltd., 1:18-cv-01838. The docket reflects a standard Paragraph IV framework: Genzyme’s complaint alleging patent infringement, Cipla’s responsive filings, and subsequent case management toward a merits and/or injunction outcome.

Court: U.S. District Court for the District of Massachusetts (D. Mass.)
Case number: 1:18-cv-01838
Parties (as styled): Genzyme Corp. v. Cipla Limited
Primary legal vehicle: Hatch-Waxman Act, 35 U.S.C. § 271(e)(2) (Paragraph IV infringement case)
Status: Not determinable from the information available in this prompt alone.

What does Genzyme Corp. v. Cipla Limited (1:18-cv-01838) allege?

Answer: The case is a patent infringement action tied to an FDA approval pathway, where Genzyme asserted infringement of one or more Orange Book-listed patents by Cipla’s proposed FDA product.

In Hatch-Waxman Paragraph IV matters, the “shape” of the pleadings is consistent:

• Genzyme alleges that Cipla’s ANDA (or related submission) seeks approval to market a drug that infringes listed patents for the reference-listed drug.
• Cipla denies infringement and/or invalidity of the asserted claims.
• The court addresses claim construction, validity, infringement, and any equitable factors for injunctive relief.

Which patents were asserted in Genzyme v. Cipla (1:18-cv-01838)?

Answer: Not determinable from the information provided in the prompt.

Patent infringement cases at this scale typically list:

• Method-of-use patents (if the Orange Book includes them)
• Formulation or composition-of-matter patents (if present)
• Drug substance or manufacturing-related patents (less common in ANDA listings, but possible via process or polymorph strategy)

The asserted patent numbers, claim sets, and expiration dates are required to produce a complete infringement and non-infringement/invalidity map. Those specifics are not present in the prompt text.

What are the key claim themes in Hatch-Waxman suits like 1:18-cv-01838?

Answer: Common themes in Genzyme-style estate litigation include infringement construction and validity challenges anchored in novelty, obviousness, enablement, written description, indefiniteness, and lack of anticipation by prior art.

Even without the asserted claims text, the litigation mechanics usually follow these analytical lanes:

• Claim construction: Court construes disputed terms; this can determine infringement.
• Infringement: The accused drug’s labeling and/or technical parameters are compared to claim limitations.
• Invalidity: Cipla typically attacks one or more of anticipation/obviousness, written description, enablement, and indefiniteness.

How does Paragraph IV timing work in Genzyme v. Cipla?

Answer: The case is tied to a generic approval attempt, where the filing date generally matters for 30-month stay logic, settlement timelines, and entry-at-risk dates.

In Paragraph IV cases:

• A first-filer ANDA triggers a potential 30-month stay of approval if suit is timely.
• The court’s pace relative to patent expiration determines whether launch is blocked or possible “at-risk.”
• If patents are adjudicated invalid/non-infringing, the generics can often enter as soon as FDA approval issues.

For this specific docket, the decision date, any preliminary injunction rulings, and whether there was a settlement are not available in the prompt.

What is the litigation procedural history for 1:18-cv-01838?

Answer: Not determinable from the information provided in the prompt.

A complete procedural summary normally includes:

• Complaint filing date
• Service and answer timeline
• Rule 12 motions (if any)
• Scheduling order dates
• Markman (if claim construction occurred)
• Summary judgment and/or final judgment milestones
• Notice of dismissal (if settled) or consent judgments (if resolved)

Those docket event dates are not included in the prompt, so an accurate chronology cannot be generated.

How strong is Genzyme’s patent estate in cases like this?

Answer: Not determinable from the information provided in the prompt.

A strength analysis requires:

• Patent claim breadth
• Priority dates and remaining life
• Prior art landscape
• Litigation history on the same patents
• Any claim narrowing constructions from prior cases

None of these elements can be mapped to 1:18-cv-01838 without the asserted patent list and case outcome.

What is Cipla’s typical defense strategy in Paragraph IV suits?

Answer: Not determinable for this specific docket from the prompt.

Cipla’s positions in Hatch-Waxman litigation typically include:

• Non-infringement based on formulation/composition or dosing regimen differences
• Invalidity based on prior art and legal grounds under 35 U.S.C. §§ 102, 103, 112, 101, and related doctrines
• Procedural defenses (standing, statutory compliance) when applicable

To assess effectiveness, the court’s rulings and final disposition are required.

Did the parties reach a settlement or consent judgment?

Answer: Not determinable from the information provided in the prompt.

Settlement is common in Paragraph IV cases and often results in:

• Dismissal without prejudice after entry of a settlement agreement
• Consent judgments
• Payment-for-delay structures (if present) and related disclosure obligations
• Delayed launch around identified “carve-out” dates tied to patent expiration

No settlement terms or docket dispositions are included in the prompt.

What is the FDA and Orange Book status impact of 1:18-cv-01838?

Answer: Not determinable from the information provided in the prompt.

Orange Book status drives:

• Which patents were listed against the reference product
• Which patents were challenged (Paragraph IV)
• Whether FDA issued a “tentative approval” and when
• Practical launch risk for the generic

Without the reference product name and the Orange Book-listed patents, the FDA impact cannot be stated accurately.

What generic entry risks exist for Cipla (and other ANDA filers) after this case?

Answer: Not determinable from the information provided in the prompt.

Entry risk is usually resolved by:

• Court validity/infringement findings against the asserted patents
• Any injunctions entered or vacated
• Patent expiration and stay periods
• Whether a design-around was accepted by FDA and whether it avoids infringement

The prompt provides no outcome.

How does Genzyme v. Cipla compare with other Genzyme Hatch-Waxman fights?

Answer: Not determinable from the information provided in the prompt.

A comparative analysis requires:

• Similar asserted patents across multiple defendants
• Common claim construction outcomes
• Patterns in how Genzyme’s patents have been upheld or invalidated

No cross-case data is present in the prompt.

Timeline (case-level)

Answer: Not determinable from the information provided in the prompt.

A correct timeline would list:

• Filing date of complaint
• ANDA submission date (if publicly referenced)
• Patent list/Orange Book listing dates (if included)
• Court scheduling milestones
• Any decision and final disposition date

Key Takeaways

• This docket is a Hatch-Waxman Paragraph IV infringement action by Genzyme against Cipla tied to an FDA approval attempt.
• A detailed litigation summary cannot be completed from the prompt alone because the asserted patent list, procedural chronology, and final disposition are not included.
• Any business conclusions about injunction risk, market entry timing, or patent strength require the case outcome and the specific patents asserted.

FAQs

1. What is the legal standard under 35 U.S.C. § 271(e)(2) for Hatch-Waxman cases like this?
2. Do Paragraph IV suits require proof of actual infringement by the generic product, or only the ANDA-relevant infringement “as if” marketed?
3. How do court claim construction decisions typically affect infringement outcomes in ANDA patent cases?
4. What determines whether 30-month stay applies in a Hatch-Waxman suit filed as a Paragraph IV?
5. When a case ends via settlement, how do consent judgments typically influence FDA approval timing?

References

No sources are provided in the prompt to support citations for this specific docket.